share_log

SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6

Benzinga Real-time News ·  Jan 27, 2023 06:48

SVB Leerink analyst Roanna Ruiz maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Market Perform and lowers the price target from $8 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment